

STATE OF NORTH CAROLINA

WAKE COUNTY

IN THE GENERAL COURT OF JUSTICE

SUPERIOR COURT DIVISION

21 CVS \_\_\_\_\_

STATE OF NORTH CAROLINA *ex rel.*

JOSHUA H. STEIN, ATTORNEY GENERAL

Plaintiff,

v.

BOSTON SCIENTIFIC CORPORATION

Defendant.

2021 MAR 23 A 11:15

GENERAL GOV. C.S.C.

Handwritten signature and vertical line of closing parentheses )

**COMPLAINT**

**INTRODUCTION**

Plaintiff State of North Carolina, by and through its Attorney General, brings this action against Defendant Boston Scientific Corporation pursuant to North Carolina’s Unfair and Deceptive Trade Practices Act, N.C.G.S. §§ 75-1.1, *et seq.* Plaintiff seeks a permanent injunction, costs, and other appropriate relief.

PLAINTIFF COMPLAINS OF DEFENDANTS AND ALLEGES AND SAYS AS FOLLOWS:

**The Parties**

1. Plaintiff is the State of North Carolina acting on relation of its Attorney General, Joshua H. Stein, who brings this action pursuant to authority found in Chapters 75 and 114 of the North Carolina General Statutes.
2. Defendant Boston Scientific Corporation (“Boston Scientific”) is a Delaware corporation and headquartered at 300 Boston Scientific Way, Marlborough, MA 01752-1234.
3. At all times relevant hereto, Defendant Boston Scientific transacted business in the State of North Carolina and nationwide by marketing, promoting, advertising, offering for sale, selling,

and distributing transvaginal surgical mesh devices, and that business is governed by the North Carolina Unfair and Deceptive Trade Practices Act, N.C.G.S. §§ 75-1.1, *et seq.*

### **Background**

4. “Surgical Mesh,” as used in this Complaint, is a medical device that contains synthetic polypropylene mesh intended to be implanted in the pelvic floor to treat stress urinary incontinence (SUI) and/or pelvic organ prolapse (POP) manufactured and sold by Boston Scientific in the United States.

5. SUI and POP are common conditions that pose lifestyle limitations and are not life-threatening.

6. SUI is a leakage of urine during episodes of physical activity that increase abdominal pressure, such as coughing, sneezing, laughing, or exercising. SUI can happen when pelvic tissues and muscles supporting the bladder and urethra become weak and allow the neck of the bladder to descend during bursts of physical activity, and the descent can prevent the urethra from working properly to control the flow of urine. SUI can also result when the sphincter muscle that controls the urethra weakens and is not able to stop the flow of urine under normal circumstances and with an increase in abdominal pressure.

7. POP happens when the tissue and muscles of the pelvic floor fail to support the pelvic organs resulting in the drop of the pelvic organs from their normal position. Not all women with POP have symptoms, while some experience pelvic discomfort or pain, pressure, and other symptoms.

8. In addition to addressing symptoms, such as wearing absorbent pads, there are a variety of non-surgical and surgical treatment options to address SUI and POP. Non-surgical options for SUI include pelvic floor exercises, pessaries, transurethral bulking agents, and behavior

modifications. Surgery for SUI can be done through the vagina or abdomen to provide support for the urethra or bladder neck with either stitches alone, tissue removed from other parts of the body, tissue from another person, or with material such as surgical mesh, which is permanently implanted. Non-surgical options for POP include pelvic floor exercises and pessaries. Surgery for POP can be done through the vagina or abdomen using stitches alone or with the addition of surgical mesh.

9. Boston Scientific marketed and sold Surgical Mesh devices to be implanted transvaginally for the treatment of POP for approximately 10 years or more. Boston Scientific ceased the sale of Surgical Mesh devices to be implanted transvaginally for the treatment of POP after the Food and Drug Administration (FDA) ordered manufacturers of such products to cease the sale and distribution of the products in April 2019.

10. Boston Scientific began marketing and selling Surgical Mesh devices to be implanted transvaginally for the treatment of SUI by 2003, and continues to market and sell Surgical Mesh devices to be implanted transvaginally for the treatment of SUI.

11. The FDA applies different levels of scrutiny to medical devices before approving or clearing them for sale.

12. The most rigorous level of scrutiny is the premarket approval (PMA) process, which requires a manufacturer to submit detailed information to the FDA regarding the safety and effectiveness of its device.

13. The 510(k) review is a much less rigorous process than the PMA review process. Under this process, a manufacturer is exempt from the PMA process and instead provides premarket notification to the FDA that a medical device is “substantially equivalent” to a legally marketed device. While PMA approval results in a finding of safety and effectiveness based on the

manufacturer's submission and any other information before the FDA, 510(k) clearance occurs after a finding of substantial equivalence to a legally marketed device. The 510(k) process is focused on equivalence, not safety.

14. Boston Scientific's SUI and POP Surgical Mesh devices entered the market under the 510(k) review process. Boston Scientific marketed and sold Surgical Mesh devices without adequate testing.

#### **Boston Scientific's Course of Conduct**

15. In marketing Surgical Mesh devices, Boston Scientific misrepresented and failed to disclose the full range of risks and complications associated with the devices, including misrepresenting the risks of Surgical Mesh as compared with the risks of other surgeries or surgically implantable materials.

16. Boston Scientific misrepresented the safety of its Surgical Mesh by misrepresenting the risks of its Surgical Mesh, thereby making false and/or misleading representations about its risks.

17. Boston Scientific also made material omissions when it failed to disclose the risks of its Surgical Mesh.

18. Boston Scientific misrepresented and/or failed to adequately disclose serious risks and complications of one or more of its transvaginally-placed Surgical Mesh products, including the following:

- a. heightened risk of infection;
- b. rigid scar plate formation;
- c. mesh shrinkage;
- d. voiding dysfunction;
- e. de novo incontinence;

- f. urinary tract infection;
- g. risk of delayed occurrence of complications; and
- h. defecatory dysfunction.

19. Throughout its marketing of Surgical Mesh, Boston Scientific continually failed to disclose risks and complications it knew to be inherent in the devices and/or misrepresented those inherent risks and complications as caused by physician error, surgical technique, or perioperative risks.

20. In 2008, the FDA issued a Public Health Notification to inform doctors and patients about serious complications associated with surgical mesh placed through the vagina to treat POP or SUI. In 2011, the FDA issued a Safety Communication to inform doctors and patients that serious complications associated with surgical mesh for the transvaginal repair of POP are not rare, and that a systematic review of published literature showed that transvaginal POP repair with mesh does not improve symptomatic results or quality of life over traditional non-mesh repair and that mesh used in transvaginal POP repair introduces risks not present in traditional non-mesh surgery for POP repair.

21. In 2012, the FDA ordered post-market surveillance studies by manufacturers of surgical mesh to address specific safety and effectiveness concerns related to surgical mesh used for the transvaginal repair of POP. In 2016, the FDA issued final orders to reclassify transvaginal POP devices as Class III (high risk) devices and to require manufacturers to submit a PMA application to support the safety and effectiveness of surgical mesh for the transvaginal repair of POP in order to continue marketing the devices.

22. In April 2019, the FDA ordered manufacturers of surgical mesh devices intended for transvaginal repair of POP to cease the sale and distribution of those products in the United States. The FDA determined that Boston Scientific had not demonstrated a reasonable assurance of safety

and effectiveness for these devices under the PMA standard. On or around April 16, 2019, Boston Scientific announced it would stop global sales of its transvaginal mesh products indicated for POP.

### VIOLATION OF LAW

23. Plaintiff realleges and incorporates by reference each and every allegation contained in the preceding paragraphs 1 through 24 as if they were set out at length herein.

24. In the course of marketing, promoting, selling, and distributing Surgical Mesh products, Boston Scientific made false statements about, misrepresented, and/or made other representations about the risks of Surgical Mesh products that had the effect, capacity, or tendency, of deceiving or misleading consumers. Pursuant to N.C.G.S. § 75-1.1, such false statements and misrepresentations constitute unfair or deceptive trade practices that are prohibited by North Carolina's Unfair and Deceptive Trade Practices Act.

25. In the course of marketing, promoting, selling, and distributing Surgical Mesh products, Boston Scientific has made representations concerning the characteristics, uses, benefits, and/or qualities of Surgical Mesh products that they did not have. Pursuant to N.C.G.S. § 75-1.1, such false statements and misrepresentations constitute unfair or deceptive trade practices that are prohibited by North Carolina's Unfair and Deceptive Trade Practices Act.

26. Defendant Boston Scientific made material omissions concerning the risks and complications associated with Surgical Mesh products, and those material omissions had the effect, capacity, or tendency of deceiving consumers. Pursuant to N.C.G.S. § 75-1.1, such omissions constitute unfair or deceptive trade practices that are prohibited by North Carolina's Unfair and Deceptive Trade Practices Act.

27. The acts or practices described herein occurred in trade or commerce as defined in North Carolina's Unfair and Deceptive Trade Practices Act.

28. These acts or practices affected the public interest because they impacted numerous North Carolina consumers.

**PRAYER FOR RELIEF**

WHEREFORE, Plaintiff prays for the following relief:

A. That this Court, pursuant to N.C.G.S. § 75-1.1, permanently enjoin and restrain Defendant, their agents, employees, and all other persons and entities, corporate or otherwise, in active concert or participation with any of them, from engaging in unfair or deceptive trade practices in the marketing, promoting, selling and distributing of Defendant's Surgical Mesh devices;

B. That this Court fashion equitable relief to cure Defendant's deceptive practices;

C. That this Court order Defendant to pay all costs for the prosecution and investigation of this action, as provided by N.C.G.S. § 75-16.1; and

D. That this Court grant such other and further relief as the Court deems just and proper.

This the 23rd day of March, 2021.

JOSHUA H. STEIN  
Attorney General



Kimberley A. D'Arruda  
Special Deputy Attorney General  
N.C. Department of Justice  
P.O. Box 629  
Raleigh, NC 27602-0629  
(919) 716-6000  
[kdarruda@ncdoj.gov](mailto:kdarruda@ncdoj.gov)  
State Bar No. 25271